Loading the company…
Loading the company…
㈜삼광랩트리
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Seoul, founded in 2018. Industry: R&D & Professional Services. Revenue for 2025 was ₩41.2bn. It has 351 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2024-05-30 · newest first
본 명세서에서는, MYLK2 (myosin light chain kinase 2) 또는 RP11-960L18.1 (lincRNA with phospholipase C gamma 2) 유전자의 CpG 부위의 메틸화 수준을 측정하는 제제를 포함하는, 대사이상 관련 지방간염의 진단용 조성물 및 이를 포함하는 키트와, 이를 이용한 대사이상 관련 지방간염 진단에 대한 정보 제공 방법이 제공된다.
본 발명은 일본뇌염바이러스 게놈 영역 중에서 구조 단백질의 일부를 암호화하는 뉴클레오타이드 서열이 삽입된 재조합 백시니아 바이러스 발현 벡터와, 재조합 바이러스 발현 벡터를 유효 성분으로 함유하는 백신 조성물에 관한 것이다. 본 발명의 재조합 백시니아 바이러스 벡터를 생체에 투여하여 생체 내에서 면역 반응을 효율적으로 유도할 수 있다. 따라서, 재조합 백시니아 바이러스 벡터는 일본뇌염바이러스에 의해 야기되는 일본 뇌염을 효율적으로 예방할 수 있는 백신으로 활용될 수 있다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 40.9 | 41.2 |
| Cost of sales | 38.8 | 38.1 |
| Gross profit (loss) | 2.1 | 3.1 |
| Selling, general and administrative expenses | 6.7 | 6.0 |
| Operating income (loss) | (4.6) | (2.8) |
| Non-operating income | 1.9 | 1.5 |
| Other gains | 0.3 | 0.2 |
| Finance income | 1.6 | 1.1 |
| Other | — | 0.2 |
| Non-operating expenses | 1.1 | 0.6 |
| Other losses | 1.0 | 0.6 |
| Other | 0.1 | 0.1 |
| Profit (loss) before tax | (3.8) | (2.0) |
| Income tax expense | 0.1 | 0.5 |
| Net income (loss) | (3.9) | (2.5) |
Revenue ₩41.2bn, up 0.8% YoY.
Operating margin -6.8% (prior -11.1%).
Net income ₩-2.5bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06